MannKind Presents New Afrezza Data at Diabetes Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: NASDAQ.COM
- Clinical Data Presentation: MannKind Corporation showcased new clinical and real-world findings on Afrezza (inhaled insulin) at the American Diabetes Association's 2026 Scientific Sessions, emphasizing its potential in managing diabetes in children and adolescents, particularly following the recent FDA approval for patients aged six and older, demonstrating the company's ongoing innovation in chronic disease care.
- Efficacy and Safety: The data highlighted Afrezza's effectiveness in pediatric care, pregnancy, and use with automated insulin delivery systems, showing similar glycemic control outcomes to rapid-acting insulin while reporting higher treatment satisfaction among youth achieving HbA1c below 8%, indicating advantages in patient experience.
- Integration Analysis: Additional exploratory analyses examined Afrezza's integration with automated insulin delivery systems, providing insights into daily insulin dosing algorithms and reinforcing its role as a safe alternative for gestational diabetes, showcasing its applicability across diverse populations.
- Market Performance: Despite MNKD's stock price fluctuating between $2.30 and $6.51 over the past year, closing at $3.40 with a 3.41% drop, the expanding role of Afrezza in diabetes management is increasing market interest in its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MNKD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MNKD
Wall Street analysts forecast MNKD stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.920
Low
7.50
Averages
9.25
High
11.00
Current: 3.920
Low
7.50
Averages
9.25
High
11.00
About MNKD
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MannKind Presents New Afrezza Data at Diabetes Conference
- Clinical Data Presentation: MannKind Corporation showcased new clinical and real-world findings on Afrezza (inhaled insulin) at the American Diabetes Association's 2026 Scientific Sessions, emphasizing its potential in managing diabetes in children and adolescents, particularly following the recent FDA approval for patients aged six and older, demonstrating the company's ongoing innovation in chronic disease care.
- Efficacy and Safety: The data highlighted Afrezza's effectiveness in pediatric care, pregnancy, and use with automated insulin delivery systems, showing similar glycemic control outcomes to rapid-acting insulin while reporting higher treatment satisfaction among youth achieving HbA1c below 8%, indicating advantages in patient experience.
- Integration Analysis: Additional exploratory analyses examined Afrezza's integration with automated insulin delivery systems, providing insights into daily insulin dosing algorithms and reinforcing its role as a safe alternative for gestational diabetes, showcasing its applicability across diverse populations.
- Market Performance: Despite MNKD's stock price fluctuating between $2.30 and $6.51 over the past year, closing at $3.40 with a 3.41% drop, the expanding role of Afrezza in diabetes management is increasing market interest in its future performance.
See More
MannKind Releases New Data Supporting Afrezza Safety and Efficacy
- FDA Approval for Children: On May 29, 2026, the FDA approved Afrezza for use in children and adolescents aged 6 and older, marking a significant advancement in diabetes treatment that is expected to substantially increase market demand and enhance MannKind's competitive position.
- Increased Treatment Satisfaction: In the INHALE-1 study, pediatric participants achieving HbA1c <8% reported significantly higher treatment satisfaction with inhaled insulin compared to rapid-acting insulin, indicating Afrezza's potential to improve patients' quality of life and possibly drive broader clinical adoption.
- Gestational Diabetes Findings: Preliminary analysis shows that inhaled insulin demonstrated comparable efficacy to rapid-acting insulin in gestational diabetes patients, with a lower incidence of hypoglycemic events, providing new possibilities for its application in special populations and further expanding market prospects.
- Personalized Treatment Strategies: Exploratory analysis suggests that the use of inhaled insulin with automated insulin delivery systems may yield varying glycemic outcomes based on total daily dose algorithms, offering new insights for future personalized diabetes management that could enhance patient adherence to treatment.
See More
MannKind Advances Clinical Trials for Inhaled IPF Therapy
- Clinical Trial Progress: On June 3, MannKind completed patient randomization for its nintedanib DPI program, marking a key milestone in its clinical efforts for idiopathic pulmonary fibrosis, with data from the INFLO-1 trial expected in Q3 2026.
- Global Research Network: The Phase 2 INFLO-2 trial will recruit approximately 210 participants across 85 global sites, utilizing a randomized double-blind design to evaluate the safety, tolerability, and optimal dosing of nintedanib DPI, aiming to establish a new standard of care.
- Innovative Technology Application: This therapy employs MannKind's proprietary Technosphere technology to deliver medication directly to the lungs, aiming to enhance treatment tolerability while minimizing systemic side effects associated with the currently approved oral form of nintedanib, thereby improving long-term patient adherence.
- Therapeutic Potential Assessment: The trial includes a 12-week treatment period followed by a 24-week open-label extension to assess secondary efficacy endpoints, including lung function and patient-reported outcomes, further defining the therapy's potential as a new standard for idiopathic pulmonary fibrosis.
See More
Analysts' Perspectives on Multiple Companies' Stock Performances
- Photronics Earnings Miss: Photronics reported disappointing quarterly results, leading analysts to place the stock in a 'penalty box' until the next quarter, indicating market caution regarding its future performance.
- Woodward Valuation Outlook: Analysts regard Woodward as a strong company, predicting a price-to-earnings ratio of 40 times, highlighting the rising demand for industrial engines under current government policies, which suggests competitive strength and growth potential.
- MannKind Investment Risks: MannKind is viewed as a speculative stock, with analysts noting that while it may attract speculative interest, investors should focus on other earnings-oriented stocks, reflecting concerns about the company's future profitability.
- Occidental Petroleum War Impact: Occidental Petroleum's stock is sensitive to geopolitical risks, with analysts warning that if the war ends, the stock could decline significantly, showcasing the market's sensitivity to such external factors.
See More
Jim Cramer's Insights on Multiple Stocks
- JFrog Stock Advice: Jim Cramer advises investors to take some profits on JFrog shares, noting that while software development is a solid business, the current valuation multiple is too high, potentially impacting future earnings.
- Becton Dickinson Investment Opportunity: Cramer highlights that Becton Dickinson's stock is currently at its lowest market level, recommending investors to buy in to capitalize on potential rebound opportunities.
- Banco Santander Market Performance: Despite Banco Santander's recent stock run-up, Cramer suggests investors hold their positions and consider buying if the stock dips back to $10, optimizing their investment strategy.
- Backblaze and Starfighters Space: Cramer expresses limited knowledge about Backblaze and Starfighters Space, refraining from providing specific investment advice, indicating a cautious stance towards these stocks.
See More
MannKind Advances Nintedanib DPI Clinical Trials
- Clinical Trial Progress: MannKind Corporation announced the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and the enrollment of the first patient in the global Phase 2 INFLO-2 study, marking significant advancement in the nintedanib DPI program, which aims to offer new treatment options for chronic idiopathic pulmonary fibrosis (IPF).
- Data Release Anticipation: Data from the INFLO-1 study is expected to be reported in Q3 2026, providing an initial assessment of safety, tolerability, and pharmacokinetics of nintedanib DPI in IPF patients, potentially laying the groundwork for further clinical development.
- Global Recruitment Plan: The Phase 2 study plans to enroll approximately 210 participants across about 85 sites worldwide, utilizing a 1:1:1 randomization to assess the safety and tolerability of nintedanib DPI while exploring its potential efficacy on lung function, demonstrating MannKind's commitment to addressing significant unmet medical needs in IPF.
- Technological Innovation Advantage: Nintedanib DPI leverages MannKind's Technosphere® dry powder inhalation technology to deliver the drug directly to the lungs, reducing systemic exposure, thereby enhancing tolerability and treatment adherence, and potentially facilitating future combination therapies with other IPF treatments.
See More
MannKind Presents New Afrezza Data at Diabetes Conference
- Clinical Data Presentation: MannKind Corporation showcased new clinical and real-world findings on Afrezza (inhaled insulin) at the American Diabetes Association's 2026 Scientific Sessions, emphasizing its potential in managing diabetes in children and adolescents, particularly following the recent FDA approval for patients aged six and older, demonstrating the company's ongoing innovation in chronic disease care.
- Efficacy and Safety: The data highlighted Afrezza's effectiveness in pediatric care, pregnancy, and use with automated insulin delivery systems, showing similar glycemic control outcomes to rapid-acting insulin while reporting higher treatment satisfaction among youth achieving HbA1c below 8%, indicating advantages in patient experience.
- Integration Analysis: Additional exploratory analyses examined Afrezza's integration with automated insulin delivery systems, providing insights into daily insulin dosing algorithms and reinforcing its role as a safe alternative for gestational diabetes, showcasing its applicability across diverse populations.
- Market Performance: Despite MNKD's stock price fluctuating between $2.30 and $6.51 over the past year, closing at $3.40 with a 3.41% drop, the expanding role of Afrezza in diabetes management is increasing market interest in its future performance.
See More
MannKind Releases New Data Supporting Afrezza Safety and Efficacy
- FDA Approval for Children: On May 29, 2026, the FDA approved Afrezza for use in children and adolescents aged 6 and older, marking a significant advancement in diabetes treatment that is expected to substantially increase market demand and enhance MannKind's competitive position.
- Increased Treatment Satisfaction: In the INHALE-1 study, pediatric participants achieving HbA1c <8% reported significantly higher treatment satisfaction with inhaled insulin compared to rapid-acting insulin, indicating Afrezza's potential to improve patients' quality of life and possibly drive broader clinical adoption.
- Gestational Diabetes Findings: Preliminary analysis shows that inhaled insulin demonstrated comparable efficacy to rapid-acting insulin in gestational diabetes patients, with a lower incidence of hypoglycemic events, providing new possibilities for its application in special populations and further expanding market prospects.
- Personalized Treatment Strategies: Exploratory analysis suggests that the use of inhaled insulin with automated insulin delivery systems may yield varying glycemic outcomes based on total daily dose algorithms, offering new insights for future personalized diabetes management that could enhance patient adherence to treatment.
See More
MannKind Advances Clinical Trials for Inhaled IPF Therapy
- Clinical Trial Progress: On June 3, MannKind completed patient randomization for its nintedanib DPI program, marking a key milestone in its clinical efforts for idiopathic pulmonary fibrosis, with data from the INFLO-1 trial expected in Q3 2026.
- Global Research Network: The Phase 2 INFLO-2 trial will recruit approximately 210 participants across 85 global sites, utilizing a randomized double-blind design to evaluate the safety, tolerability, and optimal dosing of nintedanib DPI, aiming to establish a new standard of care.
- Innovative Technology Application: This therapy employs MannKind's proprietary Technosphere technology to deliver medication directly to the lungs, aiming to enhance treatment tolerability while minimizing systemic side effects associated with the currently approved oral form of nintedanib, thereby improving long-term patient adherence.
- Therapeutic Potential Assessment: The trial includes a 12-week treatment period followed by a 24-week open-label extension to assess secondary efficacy endpoints, including lung function and patient-reported outcomes, further defining the therapy's potential as a new standard for idiopathic pulmonary fibrosis.
See More
Analysts' Perspectives on Multiple Companies' Stock Performances
- Photronics Earnings Miss: Photronics reported disappointing quarterly results, leading analysts to place the stock in a 'penalty box' until the next quarter, indicating market caution regarding its future performance.
- Woodward Valuation Outlook: Analysts regard Woodward as a strong company, predicting a price-to-earnings ratio of 40 times, highlighting the rising demand for industrial engines under current government policies, which suggests competitive strength and growth potential.
- MannKind Investment Risks: MannKind is viewed as a speculative stock, with analysts noting that while it may attract speculative interest, investors should focus on other earnings-oriented stocks, reflecting concerns about the company's future profitability.
- Occidental Petroleum War Impact: Occidental Petroleum's stock is sensitive to geopolitical risks, with analysts warning that if the war ends, the stock could decline significantly, showcasing the market's sensitivity to such external factors.
See More
Jim Cramer's Insights on Multiple Stocks
- JFrog Stock Advice: Jim Cramer advises investors to take some profits on JFrog shares, noting that while software development is a solid business, the current valuation multiple is too high, potentially impacting future earnings.
- Becton Dickinson Investment Opportunity: Cramer highlights that Becton Dickinson's stock is currently at its lowest market level, recommending investors to buy in to capitalize on potential rebound opportunities.
- Banco Santander Market Performance: Despite Banco Santander's recent stock run-up, Cramer suggests investors hold their positions and consider buying if the stock dips back to $10, optimizing their investment strategy.
- Backblaze and Starfighters Space: Cramer expresses limited knowledge about Backblaze and Starfighters Space, refraining from providing specific investment advice, indicating a cautious stance towards these stocks.
See More
MannKind Advances Nintedanib DPI Clinical Trials
- Clinical Trial Progress: MannKind Corporation announced the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and the enrollment of the first patient in the global Phase 2 INFLO-2 study, marking significant advancement in the nintedanib DPI program, which aims to offer new treatment options for chronic idiopathic pulmonary fibrosis (IPF).
- Data Release Anticipation: Data from the INFLO-1 study is expected to be reported in Q3 2026, providing an initial assessment of safety, tolerability, and pharmacokinetics of nintedanib DPI in IPF patients, potentially laying the groundwork for further clinical development.
- Global Recruitment Plan: The Phase 2 study plans to enroll approximately 210 participants across about 85 sites worldwide, utilizing a 1:1:1 randomization to assess the safety and tolerability of nintedanib DPI while exploring its potential efficacy on lung function, demonstrating MannKind's commitment to addressing significant unmet medical needs in IPF.
- Technological Innovation Advantage: Nintedanib DPI leverages MannKind's Technosphere® dry powder inhalation technology to deliver the drug directly to the lungs, reducing systemic exposure, thereby enhancing tolerability and treatment adherence, and potentially facilitating future combination therapies with other IPF treatments.
See More
